{"filing":{"accession_number":"0001437749-26-024009","cik":"0000946486","ticker":"WINT","company_name":"WINDTREE THERAPEUTICS INC /DE/","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"wint20260721_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774926024009/wint20260721_8k.htm"},"events":[{"id":19261,"run_id":17324,"accession_number":"0001437749-26-024009","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Windtree Therapeutics signed an Asset Purchase Agreement dated December 16, 2025, to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. This constitutes a material disposition of assets—specifically the transfer of drug development programs and intellectual property—with contingent consideration including a $700k payment upon a qualified financing and 20% of future licensing revenues. The agreement explicitly identifies this as an asset sale transaction under Item 1.01 (Entry into a Material Definitive Agreement), and the transfer of core drug development assets represents a material change in the company's business portfolio.","company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":[{"id":18307,"accession_number":"0001437749-26-024009","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Windtree Therapeutics signed an Asset Purchase Agreement dated December 16, 2025, to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. This constitutes a material disposition of assets—specifically the transfer of drug development programs and intellectual property—with contingent consideration including a $700k payment upon a qualified financing and 20% of future licensing revenues. The agreement explicitly identifies this as an asset sale transaction under Item 1.01 (Entry into a Material Definitive Agreement), and the transfer of core drug development assets represents a material change in the company's business portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:01:54.086922+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18307,"accession_number":"0001437749-26-024009","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Windtree Therapeutics signed an Asset Purchase Agreement dated December 16, 2025, to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. This constitutes a material disposition of assets—specifically the transfer of drug development programs and intellectual property—with contingent consideration including a $700k payment upon a qualified financing and 20% of future licensing revenues. The agreement explicitly identifies this as an asset sale transaction under Item 1.01 (Entry into a Material Definitive Agreement), and the transfer of core drug development assets represents a material change in the company's business portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:01:54.086922+00:00","company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","filing_date":"2026-07-21"}]}